Merck & Co. stock heads to HIV meeting with pipeline update
Published on 11/03/2026 at 13:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSHIV pipeline moves toward Glasgow
- Merck will present treatment and prevention findings at HIV Drug Therapy Glasgow from November 8 to 11.
- Phase 3 subgroup analyses will cover once-weekly islatravir and lenacapavir in suppressed adults with HIV.
- The FDA set an April 22, 2027, action date for two supplemental IDVYNSO applications.
Merck & Co. announced on Monday, November 2, that it will present new findings from its HIV treatment and prevention pipeline at HIV Drug Therapy Glasgow 2026. The conference runs from Sunday, November 8, through Wednesday, November 11, in Glasgow, Scotland. The company published the announcement on its Merck website.
Weekly treatment is central focus
The program will include new Phase 3 subgroup analyses for the investigational once-weekly combination of islatravir and lenacapavir, developed with Gilead Sciences. Results from the ISLEND-1 and ISLEND-2 studies will cover Week 48 safety and efficacy across demographic and clinical subgroups.
ISLEND-2 will also provide Week 48 patient-reported outcomes and a qualitative assessment of participant and provider experiences with weekly dosing. Merck said the presentations expand on Phase 3 safety and efficacy findings first presented at AIDS 2026. The treatment remains investigational and is not approved for marketing.
The company will also present results from its daily doravirine/islatravir regimen, marketed in the United States as IDVYNSO. Planned material includes Week 48 resistance and weight analyses in adults starting HIV treatment, as well as Week 96 patient-reported outcomes in adults whose HIV is virologically suppressed.
Regulatory milestones add visibility
The U.S. Food and Drug Administration has accepted two supplemental applications for IDVYNSO. One concerns adults who have not previously received antiretroviral treatment, while the other seeks to add 96-week results for virologically suppressed adults. The agency set April 22, 2027, as the target action date for both applications.
Merck is also advancing islatravir with its investigational once-weekly combination with ulonivirine. The Glasgow program includes Week 24 findings from a Phase 2b study and early clinical pharmacology work on ulonivirine. In prevention, the company will show participant demographics from two ongoing Phase 3 studies of alimatravir, an investigational once-monthly oral pre-exposure prophylaxis. Adult enrollment in both trials is complete.
Pipeline broadens the investor debate
The HIV announcement gives investors a forward-looking pipeline event after Merck's third-quarter report and higher 2026 outlook. It does not change the regulatory or commercial status of the investigational programs, but the breadth of the presentation offers a read-through on the company's effort to develop treatment and prevention options with less frequent dosing.
Merck & Co. stock traded at 131.80 euros on Lang & Schwarz at 13:38 CET on Tuesday, November 3, 2026, 0.51 percent below the Xetra close of Monday, November 2. The quote was captured while the Xetra session was open, so the comparison uses the prior Xetra close.
Investors will next look to the HIV Glasgow presentations for subgroup results, treatment-preference findings and further detail on the once-weekly programs. The FDA's April 2027 action date provides the next defined regulatory milestone for IDVYNSO.
For the broader market backdrop, see current S&P 500 market coverage.
Follow the real-time quote of Merck & Co. stock for the latest trading indication.
Merck & Co. stock at a glance
- Company: Merck & Co., Inc.
- ISIN: US58933Y1055
- Trading venue: Lang & Schwarz
- Quote: 131.80 euros at 13:38 CET on Tuesday, November 3, 2026
- Daily comparison: 0.51 percent below the Xetra close of Monday, November 2, at 132.48 euros
More news and analyses on Merck & Co. stock.
